Public Employees Retirement System of Ohio Buys 1,941 Shares of Medpace Holdings, Inc. $MEDP

Public Employees Retirement System of Ohio increased its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 12.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,968 shares of the company's stock after buying an additional 1,941 shares during the period. Public Employees Retirement System of Ohio owned 0.06% of Medpace worth $8,628,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in MEDP. AQR Capital Management LLC grew its stake in Medpace by 65.1% in the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company's stock valued at $518,170,000 after acquiring an additional 404,226 shares during the period. Arrowstreet Capital Limited Partnership raised its position in shares of Medpace by 205.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company's stock worth $161,523,000 after purchasing an additional 211,411 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Medpace by 158.6% in the 4th quarter. Franklin Resources Inc. now owns 299,472 shares of the company's stock worth $168,198,000 after purchasing an additional 183,645 shares in the last quarter. Norges Bank acquired a new stake in Medpace in the 4th quarter valued at $102,156,000. Finally, Goldman Sachs Group Inc. grew its position in Medpace by 92.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company's stock valued at $194,920,000 after purchasing an additional 166,654 shares during the period. 77.98% of the stock is owned by institutional investors.

Insider Activity at Medpace

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the sale, the general counsel directly owned 20,343 shares in the company, valued at $9,154,350. The trade was a 44.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 20.50% of the stock is owned by insiders.

Medpace Stock Down 2.0%

MEDP stock opened at $589.37 on Tuesday. The firm has a market cap of $16.45 billion, a PE ratio of 34.55, a P/E/G ratio of 2.68 and a beta of 1.15. The business has a 50 day moving average of $495.46 and a 200-day moving average of $493.70. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $677.90.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts' consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same period last year, the company posted $3.10 earnings per share. Medpace's quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts expect that Medpace Holdings, Inc. will post 17.59 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on MEDP. Deutsche Bank Aktiengesellschaft restated a "hold" rating and set a $535.00 price target on shares of Medpace in a research note on Thursday. Royal Bank Of Canada lifted their price objective on shares of Medpace from $484.00 to $692.00 and gave the company an "outperform" rating in a report on Friday. Truist Financial boosted their target price on shares of Medpace from $462.00 to $609.00 and gave the stock a "hold" rating in a research report on Friday. Mizuho raised their price target on shares of Medpace from $586.00 to $665.00 and gave the company an "outperform" rating in a research report on Friday. Finally, TD Cowen lifted their price target on Medpace from $419.00 to $492.00 and gave the company a "hold" rating in a research note on Friday. Two research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $560.92.

Medpace Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.